Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BMRN 
Biomarin Pharmaceutical Inc (BMRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BMRN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
29 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $97.62
1 Year Target Price $97.62
| 16 | Strong Buy |
| 7 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.99% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.26B USD | Price to earnings Ratio 17.01 | 1Y Target Price 97.62 |
Price to earnings Ratio 17.01 | 1Y Target Price 97.62 | ||
Volume (30-day avg) 29 | Beta 0.18 | 52 Weeks Range 52.93 - 92.81 | Updated Date 08/28/2025 |
52 Weeks Range 52.93 - 92.81 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When - | Estimate 0.83 | Actual 1.44 |
Profitability
Profit Margin 21.45% | Operating Margin (TTM) 33.55% |
Management Effectiveness
Return on Assets (TTM) 7.5% | Return on Equity (TTM) 11.62% |
Valuation
Trailing PE 17.01 | Forward PE 15.67 | Enterprise Value 10247143185 | Price to Sales(TTM) 3.68 |
Enterprise Value 10247143185 | Price to Sales(TTM) 3.68 | ||
Enterprise Value to Revenue 3.34 | Enterprise Value to EBITDA 10.97 | Shares Outstanding 192015008 | Shares Floating 178101223 |
Shares Outstanding 192015008 | Shares Floating 178101223 | ||
Percent Insiders 0.78 | Percent Institutions 98.96 |
Upturn AI SWOT
Biomarin Pharmaceutical Inc
Company Overview
History and Background
BioMarin Pharmaceutical Inc. was founded in 1997. It focuses on developing and commercializing therapies for serious and life-threatening rare genetic diseases and acquired conditions. It has grown from a small research firm to a global biopharmaceutical company.
Core Business Areas
- Genetic Diseases: Development and commercialization of therapies for rare genetic diseases like phenylketonuria (PKU), mucopolysaccharidoses (MPS), and achondroplasia.
- Acquired Conditions: Development and commercialization of therapies for certain acquired conditions where genetic factors play a significant role.
- Research and Development: Extensive research and development programs focused on discovering and developing new therapies for rare diseases.
Leadership and Structure
The leadership team includes Alexander J. Denner (Chairman), Alexander J. Denner (Interim Chief Executive Officer). The organizational structure is hierarchical with distinct departments for research, development, manufacturing, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Vimizim (elosulfase alfa): An enzyme replacement therapy for Morquio A syndrome (MPS IVA). Competitors are limited due to the rarity of the disease. Vimizim generated significant revenue but market share specific details are not publicly available in detail. Sanofi has been a competitor in MPS space.
- Kuvan (sapropterin dihydrochloride): A medication for phenylketonuria (PKU). Competitors include synthetic phenylalanine lowering drugs and gene therapy approaches. Revenue is decreasing due to generic entries and competition. Precision BioSciences and Homology Medicines are working on gene therapy.
- Naglazyme (galsulfase): An enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI). Competitors are limited due to the rarity of the disease. Market share is high within its niche. No direct competitors for Naglazyme currently.
- Voxzogo (vosoritide): A therapy for achondroplasia. BioMarin's market entry here has been successful but potential competitors are emerging and revenue data is tracked. Ascendis Pharma is working on an achondroplasia treatment.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies focused on developing and commercializing novel therapies. The rare disease segment is attractive due to orphan drug designations and potentially high prices. The industry is regulated by the FDA.
Positioning
BioMarin is a leading company in the rare disease biopharmaceutical space, known for its innovative therapies and strong pipeline. Its competitive advantages include its deep expertise in enzyme replacement therapy and gene therapy.
Total Addressable Market (TAM)
The rare disease therapeutics market is expected to reach $258.76 billion by 2032. BioMarin is positioned well to capture a significant share of this TAM, particularly with its focus on genetic diseases and strong product portfolio.
Upturn SWOT Analysis
Strengths
- Strong product portfolio of approved therapies for rare diseases
- Deep expertise in enzyme replacement therapy and gene therapy
- Established commercial infrastructure and global reach
- Strong pipeline of product candidates in clinical development
- Orphan drug designations providing market exclusivity
Weaknesses
- High reliance on a small number of key products
- Competition from biosimilars and generics
- Regulatory and reimbursement challenges
- High research and development costs
- Potential for clinical trial failures
Opportunities
- Expanding into new rare disease indications
- Developing innovative gene therapy products
- Acquiring or licensing promising product candidates
- Expanding into emerging markets
- Leveraging its expertise to develop therapies for more common diseases
Threats
- Increased competition from other biopharmaceutical companies
- Changes in regulatory landscape and reimbursement policies
- Clinical trial failures
- Intellectual property disputes
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- SANOY
- LLY
- GILD
- REGN
Competitive Landscape
BioMarin benefits from its focus on ultra-rare diseases, granting them somewhat insulated markets and allowing for premium pricing. Compared to competitors, BioMarin has greater specialized expertise within the ultra-rare market. BioMarin's disadvantage is it's smaller size and resources relative to the competitors above.
Major Acquisitions
Prosensa
- Year: 2014
- Acquisition Price (USD millions): 840
- Strategic Rationale: Expanded BioMarinu2019s pipeline with a promising Duchenne muscular dystrophy therapy (drisapersen).
Growth Trajectory and Initiatives
Historical Growth: BioMarin has experienced significant revenue growth over the past decade, driven by the commercial success of its rare disease therapies.
Future Projections: Future growth is expected to be driven by the launch of new products, expansion into new markets, and continued innovation in rare disease therapies. Analyst estimates vary depending on specific product pipelines, competition, and approval timelines.
Recent Initiatives: Recent initiatives include advancing gene therapy programs, expanding the commercial reach of Voxzogo, and investing in research and development.
Summary
BioMarin is a strong player in the rare disease biopharmaceutical space, supported by its approved therapies and innovative pipeline. Its focus on genetic diseases and enzyme replacement therapies strengthens its position. Regulatory hurdles and competitive pressures are challenges to watch. Overall, the company is well positioned for future growth, but its dependency on a few key products poses a risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Investor Relations Materials
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered as financial advice. Data is based on publicly available information and may not be fully comprehensive. Investment decisions should be based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomarin Pharmaceutical Inc
Exchange NASDAQ | Headquaters San Rafael, CA, United States | ||
IPO Launch date 1999-07-23 | President, CEO & Director Mr. Alexander Hardy | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3040 | Website https://www.biomarin.com |
Full time employees 3040 | Website https://www.biomarin.com | ||
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.